Darunavir Tablets and Prandin

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Darunavir may alter the blood levels and effects of repaglinide. This can increase the risk of hypoglycemia (low blood sugar), or in some cases, it may reduce the effectiveness of repaglinide in treating your diabetes. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, weakness, tremor, nausea, hunger, sweating, and fast or pounding heartbeats. Symptoms of hyperglycemia (high blood sugar) may include increased thirst, increased hunger, and increased urination. You should contact your doctor if you experience loss of blood sugar control. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with protease inhibitors may alter the hypoglycemic effect of repaglinide. Pharmacodynamically, protease inhibitors may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes. However, since they are potent inhibitors of CYP450 3A4, they may also increase the plasma concentrations and pharmacologic effects of repaglinide, which is partially metabolized by the isoenzyme. In healthy volunteers, other potent inhibitors of CYP450 3A4 such as clarithromycin, itraconazole, and ketoconazole have increased repaglinide systemic exposure (AUC) by 15% to 40%. The clinical significance of these changes is unknown, but may be increased in diabetics due to potentially reduced counter-regulatory response to hypoglycemia in these patients. Potent CYP450 3A4 inhibitors can also enhance the pharmacokinetic interaction between repaglinide and CYP450 2C8 and/or OATP 1B1 inhibitors such as gemfibrozil. In one pharmacokinetic study, gemfibrozil alone increased repaglinide AUC by 8-fold, while gemfibrozil plus itraconazole increased repaglinide AUC by over 19-fold. Rare cases of severe hypoglycemia have been reported in patients using this combination during postmarketing surveillance.

MANAGEMENT: Pharmacologic response to repaglinide should be monitored more closely whenever a protease inhibitor is added to or withdrawn from therapy. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations. The repaglinide dosage may require adjustment if an interaction is suspected.

Darunavir Tablets

Generic Name: darunavir

Brand name: Prezista

Synonyms: Darunavir

What is Darunavir Tablets?

Prandin

Generic Name: repaglinide

Brand name: Prandin

Synonyms: n.a.

What is Prandin?